{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-023169","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.694526+00:00","generated_at":"2026-05-15T21:28:40.174370+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026","bullets":["Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.","Cash $13.2M at Dec 31, 2025, expected to fund operations into Q3 2026.","Plans to submit Conditional Marketing Authorization for iopofosine I 131 to EMA in Q3 2026.","Initiated Phase 1b study of CLR 125 in triple negative breast cancer; early data mid-2026.","Received FDA Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory WM."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-023169","json":"https://secwatch.observer/filing/0001104659-26-023169.json","markdown":"https://secwatch.observer/filing/0001104659-26-023169.md","text":"https://secwatch.observer/filing/0001104659-26-023169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/0001104659-26-023169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/tm267955d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:28:40.174370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93bb914d5150c1e43931a84fdd9acef6cfc4850c","claim":"Cellectar Biosciences, Inc. reported the year ended December 31, 2025 results: net income $21.8 million, EPS $8.35 per basic and diluted share.","evidence_excerpt":"Net loss for the full year ending December 31, 2025, was $21.8 million or $8.35 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/0001104659-26-023169-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"$21.8 million"},{"label":"EPS","value":"$8.35 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}